Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Robert F Storey

Showing results (341-350 of 401) with videos related to

Pageof 41
Sort By:
The New England Journal of Medicine|March 19, 2019
Antithrombotic Therapy after Acute Coronary Syndrome or PCI in Atrial FibrillationRenato D Lopes, Gretchen Heizer, Ronald Aronson, et al.
ESC Heart Failure|September 17, 2025
Cardiometabolic outcomes with dapagliflozin after myocardial infarction by baseline ejection fraction: DAPA-MIDavid Erlinge, Stefan James, John Deanfield, et al.
European Heart Journal Open|June 12, 2025
Virtual physiological analysis of non-culprit disease in patients with STEMI and multivessel disease: a substudy of the COMPLETE trialGareth J Williams, Daniel J Taylor, Abdulaziz Al Baraikan, et al.
European Heart Journal|October 30, 2016
Management of antithrombotic therapy after bleeding in patients with coronary artery disease and/or atrial fibrillation: expert consensus paper of the European Society of Cardiology Working Group on ThrombosisSigrun Halvorsen, Robert F Storey, Bianca Rocca, et al.
European Heart Journal. Cardiovascular Pharmacotherapy|April 30, 2023
Antithrombotic treatment strategies in patients with established coronary atherosclerotic diseaseMarco Valgimigli, Victor Aboyans, Dominick Angiolillo, et al.
NEJM Evidence|February 6, 2024
Dapagliflozin in Myocardial Infarction without Diabetes or Heart FailureStefan James, David Erlinge, Robert F Storey, et al.
Thrombosis and Haemostasis|January 10, 2014
Effects of vorapaxar on platelet reactivity and biomarker expression in non-ST-elevation acute coronary syndromes. The TRACER Pharmacodynamic SubstudyRobert F Storey, Jayaprakash Kotha, Susan S Smyth, et al.
Circulation|July 22, 2024
Demystifying the Contemporary Role of 12-Month Dual Antiplatelet Therapy After Acute Coronary SyndromeMarco Valgimigli, Antonio Landi, Dominick J Angiolillo, et al.
American Heart Journal|October 23, 2023
Effects of complete revascularization according to age in patients with ST-segment elevation myocardial infarction and multivessel disease (COMPLETE-AGE)Kevin R Bainey, David A Wood, Matthias Bossard, et al.
European Heart Journal|July 12, 2015
Antithrombotic therapy in the elderly: expert position paper of the European Society of Cardiology Working Group on ThrombosisFelicita Andreotti, Bianca Rocca, Steen Husted, et al.
Pageof 41

Showing results (341-350 of 401) with videos related to

Sort By:
Pageof 41
The New England Journal of Medicine|March 19, 2019
Antithrombotic Therapy after Acute Coronary Syndrome or PCI in Atrial FibrillationRenato D Lopes, Gretchen Heizer, Ronald Aronson, et al.
ESC Heart Failure|September 17, 2025
Cardiometabolic outcomes with dapagliflozin after myocardial infarction by baseline ejection fraction: DAPA-MIDavid Erlinge, Stefan James, John Deanfield, et al.
European Heart Journal Open|June 12, 2025
Virtual physiological analysis of non-culprit disease in patients with STEMI and multivessel disease: a substudy of the COMPLETE trialGareth J Williams, Daniel J Taylor, Abdulaziz Al Baraikan, et al.
European Heart Journal|October 30, 2016
Management of antithrombotic therapy after bleeding in patients with coronary artery disease and/or atrial fibrillation: expert consensus paper of the European Society of Cardiology Working Group on ThrombosisSigrun Halvorsen, Robert F Storey, Bianca Rocca, et al.
European Heart Journal. Cardiovascular Pharmacotherapy|April 30, 2023
Antithrombotic treatment strategies in patients with established coronary atherosclerotic diseaseMarco Valgimigli, Victor Aboyans, Dominick Angiolillo, et al.
NEJM Evidence|February 6, 2024
Dapagliflozin in Myocardial Infarction without Diabetes or Heart FailureStefan James, David Erlinge, Robert F Storey, et al.
Thrombosis and Haemostasis|January 10, 2014
Effects of vorapaxar on platelet reactivity and biomarker expression in non-ST-elevation acute coronary syndromes. The TRACER Pharmacodynamic SubstudyRobert F Storey, Jayaprakash Kotha, Susan S Smyth, et al.
Circulation|July 22, 2024
Demystifying the Contemporary Role of 12-Month Dual Antiplatelet Therapy After Acute Coronary SyndromeMarco Valgimigli, Antonio Landi, Dominick J Angiolillo, et al.
American Heart Journal|October 23, 2023
Effects of complete revascularization according to age in patients with ST-segment elevation myocardial infarction and multivessel disease (COMPLETE-AGE)Kevin R Bainey, David A Wood, Matthias Bossard, et al.
European Heart Journal|July 12, 2015
Antithrombotic therapy in the elderly: expert position paper of the European Society of Cardiology Working Group on ThrombosisFelicita Andreotti, Bianca Rocca, Steen Husted, et al.
Pageof 41